We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy.
- Authors
Liu, Yun; Li, Yang; Wang, Yuxi; Lin, Congcong; Zhang, Dan; Chen, Juncheng; Ouyang, Liang; Wu, Fengbo; Zhang, Jifa; Chen, Lei
- Abstract
Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis. Currently, VEGFR inhibitors have been widely used in the treatment of various tumors. However, current VEGFR inhibitors are limited to a certain extent due to limited clinical efficacy and potential toxicity, which hinder their clinical application. Thus, the development of new strategies to improve the clinical outcomes and minimize the toxic effects of VEGFR inhibitors is required. Given the synergistic effect of VEGFR and other therapies in tumor development and progression, VEGFR dual-target inhibitors are becoming an attractive approach due to their favorable pharmacodynamics, low toxicity, and anti-resistant effects. This perspective provides an overview of the development of VEGFR dual-target inhibitors from multiple aspects, including rational target combinations, drug discovery strategies, structure–activity relationships and future directions.
- Subjects
VASCULAR endothelial growth factor receptors; KINASES; VASCULAR endothelial growth factor antagonists; PROTEIN kinases; STRUCTURE-activity relationships; PROTEIN receptors
- Publication
Journal of Hematology & Oncology, 2022, Vol 15, Issue 1, p1
- ISSN
1756-8722
- Publication type
Article
- DOI
10.1186/s13045-022-01310-7